<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>BREVITAL SODIUM- methohexital sodium injection, powder, lyophilized, for solution </strong><br>A-S Medication Solutions LLC<br></p></div>
<h1>BREVITAL<span class="Sup">®</span> SODIUM<br> METHOHEXITAL SODIUM FOR INJECTION, USP</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">CIV</span></p>
<p>For Intravenous Use in Adults</p>
<p>For Rectal and Intramuscular Use Only in Pediatric Patients</p>
</div>
<div class="Warning">
<a name="section-2"></a><p></p>
<h1><span class="Emphasis">WARNING</span></h1>
<p class="First"><span class="Bold">Brevital should be used only in hospital or ambulatory care settings that provide for continuous monitoring of respiratory (e.g. pulse oximetry) and cardiac function. Immediate availability of resuscitative drugs and age- and size-appropriate equipment for bag/valve/mask ventilation and intubation and personnel trained in their use and skilled in airway management should be assured. For deeply sedated patients, a designated individual other than the practitioner performing the procedure should be present to continuously monitor the patient. (See <a href="#W">WARNINGS</a>)</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Brevital<span class="Sup">®</span> Sodium (Methohexital Sodium for Injection, USP) is 2,4,6 (1<span class="Italics">H</span>, 3<span class="Italics">H</span>, 5<span class="Italics">H</span>)-Pyrimidinetrione, 1-methyl-5-(1-methyl-2-pentynyl)-5-(2-propenyl)-, (±)-, monosodium salt and has the empirical formula C<span class="Sub">14</span>H<span class="Sub">17</span>N<span class="Sub">2</span>NaO<span class="Sub">3</span>. Its molecular weight is 284.29.</p>
<p>The structural formula is as follows:</p>
<p><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=468a7188-2e77-480f-8c68-6e2e9b6b47fd&amp;name=brevital-01.jpg"></p>
<p>Methohexital sodium is a rapid, ultrashort-acting barbiturate anesthetic. Methohexital sodium for injection is a freeze-dried, sterile, nonpyrogenic mixture of methohexital sodium with 6% anhydrous sodium carbonate added as a buffer. It contains not less than 90% and not more than 110% of the labeled amount of methohexital sodium. It occurs as a white, freeze-dried plug that is freely soluble in water.</p>
<p>This product is oxygen sensitive. The pH of the 1% solution is between 10 and 11; the pH of the 0.2% solution in 5% dextrose is between 9.5 and 10.5.</p>
<p>Methohexital sodium may be administered by direct intravenous injection or continuous intravenous drip, intramuscular or rectal routes (see <span class="Bold"><a href="#P-PU">PRECAUTIONS—Pediatric Use</a></span>). Reconstituting instructions vary depending on the route of administration (see <span class="Bold"><a href="#DA">DOSAGE AND ADMINISTRATION</a></span>).</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Compared with thiamylal and thiopental, methohexital is at least twice as potent on a weight basis, and its duration of action is only about half as long. Although the metabolic fate of methohexital in the body is not clear, the drug does not appear to concentrate in fat depots to the extent that other barbiturate anesthetics do. Thus, cumulative effects are fewer and recovery is more rapid with methohexital than with thiobarbiturates. In experimental animals, the drug cannot be detected in the blood 24 hours after administration.</p>
<p>Methohexital differs chemically from the established barbiturate anesthetics in that it contains no sulfur. Little <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> is conferred by barbiturates; their use in the presence of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> may result in excitation.</p>
<p>Intravenous administration of methohexital results in rapid uptake by the brain (within 30 seconds) and rapid induction of sleep.</p>
<p>Following intramuscular administration to pediatric patients, the onset of sleep occurs in 2 to 10 minutes. A plasma concentration of 3 µg/mL was achieved in pediatric patients 15 minutes after an intramuscular dose (10 mg/kg) of a 5% solution. Following rectal administration to pediatric patients, the onset of sleep occurs in 5 to 15 minutes. Plasma methohexital concentrations achieved following rectal administration tend to increase both with dose and with the use of more dilute solution concentrations when using the same dose. A 25 mg/kg dose of a 1% methohexital solution yielded plasma concentrations of 6.9 to 7.9 µg/mL 15 minutes after dosing. The absolute bioavailability of rectal methohexital sodium is 17%.</p>
<p>With single doses, the rate of redistribution determines duration of pharmacologic effect. Metabolism occurs in the liver through demethylation and oxidation. Side-chain oxidation is the most important biotransformation involved in termination of biologic activity. Excretion occurs via the kidneys through glomerular filtration.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Brevital Sodium can be used in adults as follows:</p>
<ol>
<li>For <span class="Italics">intravenous</span> induction of anesthesia prior to the use of other general anesthetic agents.</li>
<li>For <span class="Italics">intravenous</span> induction of anesthesia and as an adjunct to subpotent inhalational anesthetic agents (such as nitrous oxide in oxygen) for short surgical procedures; Brevital Sodium may be given by infusion or intermittent injection.</li>
<li>For use along with other parenteral agents, usually narcotic analgesics, to supplement subpotent inhalational anesthetic agents (such as nitrous oxide in oxygen) for longer surgical procedures.</li>
<li>As <span class="Italics">intravenous</span> anesthesia for short surgical, diagnostic, or therapeutic procedures associated with minimal painful stimuli (see <span class="Bold"><a href="#W">WARNINGS</a></span>).</li>
<li>As an agent for inducing a hypnotic state.</li>
</ol>
<p>Brevital Sodium can be used in <span class="Underline">pediatric patients older than 1 month</span> as follows:</p>
<ol>
<li>For rectal or <span class="Italics">intramuscular induction</span>  of anesthesia prior to the use of other general anesthetic agents.</li>
<li>For rectal or <span class="Italics">intramuscular induction</span>  of anesthesia and as an adjunct to subpotent inhalational anesthetic agents for short surgical procedures.</li>
<li>As rectal or <span class="Italics">intramuscular</span> anesthesia for short surgical, diagnostic, or therapeutic procedures associated with minimal painful stimuli.</li>
</ol>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Brevital Sodium is contraindicated in patients in whom general anesthesia is contraindicated, in those with latent or manifest <span class="product-label-link" type="condition" conceptid="4305376" conceptname="Porphyria">porphyria</span>, or in patients with a known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to barbiturates.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">See <a href="#Box">boxed Warning</a>.</p>
<p>As with all potent anesthetic agents and adjuncts, Brevital should be used only in hospital or ambulatory care settings that provide for continuous monitoring of respiratory (e.g. pulse oximetry) and cardiac function. Immediate availability of resuscitative drugs and age- and size-appropriate equipment for bag/valve/mask ventilation and intubation and personnel trained in their use and skilled in airway management should be assured. For deeply sedated patients, a designated individual other than the practitioner performing the procedure should be present to continuously monitor the patient.</p>
<p>Maintenance of a patent airway and adequacy of ventilation must be ensured during induction and maintenance of anesthesia with methohexital sodium solution. <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">Laryngospasm</span> is common during induction with all barbiturates and may be due to a combination of secretions and accentuated reflexes following induction or may result from painful stimuli during <span class="product-label-link" type="condition" conceptid="4086497" conceptname="Light anesthesia">light anesthesia</span>. <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">Apnea</span>/<span class="product-label-link" type="condition" conceptid="312603" conceptname="Hypoventilation">hypoventilation</span> may be noted during induction, which may impair pulmonary ventilation; the duration of <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span> may be longer than that produced by other barbiturate anesthetics. Cardiorespiratory arrest may occur.</p>
<p>This prescribing information describes intravenous use of methohexital sodium in adults. It also discusses intramuscular and rectal administration in pediatric patients older than one month. Although the published literature discusses intravenous administration in pediatric patients, the safety and effectiveness of intravenous administration of methohexital sodium in pediatric patients have not been established in well-controlled, prospective studies. (See <span class="Bold"><a href="#P-PU">PRECAUTIONS— Pediatric Use</a></span>)</p>
<p><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> may be elicited in subjects with a previous history of convulsive activity, especially partial <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> disorders.</p>
<p>Because the liver is involved in demethylation and oxidation of methohexital and because barbiturates may enhance preexisting circulatory <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, severe hepatic dysfunction, severe cardiovascular instability, or a <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>-like condition may be reason for selecting another induction agent.</p>
<p>Prolonged administration may result in cumulative effects, including extended <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, protracted <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">unconsciousness</span>, and respiratory and cardiovascular <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>. <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory depression</span> in the presence of an impaired airway may lead to <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</p>
<p>The CNS-depressant effect of Brevital Sodium may be additive with that of other CNS depressants, including ethyl alcohol and propylene glycol.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1"></a><p></p>
<h2>DANGER OF INTRA-ARTERIAL INJECTION</h2>
<p class="First">Unintended intra-arterial injection of barbiturate solutions may be followed by the production of platelet aggregates and <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span>, starting in arterioles distal to the site of injection. The resulting <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> may lead to <span class="product-label-link" type="condition" conceptid="439928" conceptname="Gangrenous disorder">gangrene</span>, which may require amputation. The first sign in conscious patients may be a complaint of fiery burning that roughly follows the distribution path of the injected artery; if noted, the injection should be stopped immediately and the situation reevaluated. <span class="Underline">Transient</span> <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">blanching</span> <span class="Underline">may</span> or may not be noted very early; <span class="product-label-link" type="condition" conceptid="4233116" conceptname="Macular rash">blotchy</span> <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span> and dark discoloration may then be the first sign in anesthetized patients. There is no established treatment other than prevention. The following should be considered prior to injection:</p>
<ol>
<li>The extent of injury is related to concentration. Concentrations of 1% methohexital will usually suffice; higher concentrations should ordinarily be avoided.</li>
<li>Check the infusion to ensure that the catheter is in the lumen of a vein before injection. Injection through a running intravenous infusion may enhance the possibility of detecting arterial placement; however, it should be remembered that the characteristic bright-red color of arterial blood is often altered by contact with drugs. The possibility of aberrant arteries should always be considered.</li>
</ol>
<p>Postinjury arterial injection of vasodilators and/or arterial infusion of parenteral fluids are generally regarded to be of no value in altering outcome. Animal experiments and published individual case reports concerned with a variety of arteriolar irritants, including barbiturates, suggest that 1 or more of the following <span class="Underline">may</span> be of benefit in reducing the area of <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span>:</p>
<ol>
<li>Arterial injection of heparin at the site of injury, followed by systemic anticoagulation.</li>
<li>Sympathetic blockade (or brachial plexus blockade in the arm).</li>
<li>Intra-arterial glucocorticoid injection at the site of injury, followed by systemic steroids.</li>
<li>A case report (nonbarbiturate injury) suggests that intra-arterial urokinase may promote <span class="product-label-link" type="condition" conceptid="4299457" conceptname="Fibrinolysis">fibrinolysis</span>, even if administered late in treatment.</li>
</ol>
<p>If <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span> is noted during injection of methohexital, the injection should be discontinued until the situation is remedied. Local irritation may result from <span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">extravasation</span>; subcutaneous <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> may also serve as a sign of arterial or periarterial placement of the catheter.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">All routes of administration of Brevital Sodium are often associated with <span class="product-label-link" type="condition" conceptid="194475" conceptname="Hiccoughs">hiccups</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span>, and/or <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">muscle twitching</span>, which may also impair pulmonary ventilation. Following induction, temporary <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> may occur.</p>
<p>Recovery from methohexital anesthesia is rapid and smooth. The incidence of <span class="product-label-link" type="condition" conceptid="4274029" conceptname="Postoperative nausea">postoperative nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> is low if the drug is administered to fasting patients. Postanesthetic <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">shivering</span> has occurred in a few instances.</p>
<p>The usual precautions taken with any barbiturate anesthetic should be observed with Brevital Sodium. The drug should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, obstructive pulmonary disease, severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, myocardial disease, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, severe <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, or extreme <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>.</p>
<p>Methohexital sodium should be used with extreme caution in patients in status asthmaticus. Caution should be exercised in debilitated patients or in those with impaired function of respiratory, circulatory, renal, hepatic, or endocrine systems.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-7.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">When appropriate, patients should be instructed as to the hazards of <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> that may follow use of Brevital Sodium. Outpatients should be released in the company of another individual, and no skilled activities, such as operating machinery or driving a motor vehicle, should be engaged in for 8 to 12 hours.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="section-7.3"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">BSP and liver function studies may be influenced by administration of a single dose of barbiturates.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7.4"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Prior chronic administration of barbiturates or phenytoin (e.g. for <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> disorder) appears to reduce the effectiveness of Brevital Sodium. Barbiturates may influence the metabolism of other concomitantly used drugs, such as phenytoin, halothane, anticoagulants, corticosteroids, ethyl alcohol, and propylene glycol-containing solutions.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-7.5"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Studies in animals to evaluate the carcinogenic and mutagenic potential of Brevital Sodium have not been conducted. Reproduction studies in animals have revealed no evidence of impaired fertility.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-7.6"></a><p></p>
<h2>Usage in Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-7.6.1"></a><p></p>
<h3>Pregnancy Category B</h3>
<p class="First">Reproduction studies have been performed in rabbits and rats at doses up to 4 and 7 times the human dose respectively and have revealed no evidence of harm to the fetus due to methohexital sodium. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="section-7.7"></a><p></p>
<h2>Labor and Delivery</h2>
<p class="First">Brevital Sodium has been used in cesarean section delivery but, because of its solubility and lack of protein binding, it readily and rapidly traverses the placenta.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-7.8"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Caution should be exercised when Brevital Sodium is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-7.9"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">The safety and effectiveness of methohexital sodium in pediatric patients below the age of 1 month have not been established. <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> may be elicited in subjects with a previous history of convulsive activity, especially partial <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> disorders. <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">Apnea</span> has been reported following dosing with methohexital regardless of the route of administration used. Studies using methohexital sodium intravenously in pediatric patients have been reported in the published literature. This literature is not adequate to establish the safety and effectiveness of intravenous administration of methohexital sodium in pediatric patients. Due to a variety of limitations such as study design, biopharmaceutic issues, and the wide range of effects observed with similar doses of intravenous methohexital, additional studies of intravenous methohexital in pediatric patients are necessary before this route can be recommended in pediatric patients. (See <span class="Bold"><a href="#W">WARNINGS</a></span>)</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-7.10"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Clinical studies of Brevital did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. Elderly subjects may commonly have conditions in which methohexital should be used cautiously such as obstructive pulmonary disease, severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, preexisting circulatory <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, myocardial disease, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, or severe <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>. Caution should be exercised in debilitated patients or in those with impaired function of respiratory, circulatory, renal, hepatic, or endocrine systems (see <span class="Bold"><a href="#W">WARNINGS</a>, <a href="#P">PRECAUTIONS</a></span> and <span class="Bold"><a href="#AR">ADVERSE REACTIONS</a></span>). Barbiturates may influence the metabolism of other concomitantly used drugs that are commonly taken by the elderly, such as anticoagulants and corticosteroids. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy (see <span class="Bold"><a href="#P-DI">PRECAUTIONS-Drug Interactions</a></span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Side effects associated with Brevital Sodium are extensions of pharmacologic effects and include:</p>
<p><span class="Italics">Cardiovascular</span>—Circulatory <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, peripheral <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">vascular collapse</span>, and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> in association with cardiorespiratory arrest</p>
<p><span class="Italics">Respiratory</span>—<span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory depression</span> (including <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>), cardiorespiratory arrest, <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngospasm</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="194475" conceptname="Hiccoughs">hiccups</span>, and <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span></p>
<p><span class="Italics">Neurologic</span>—Skeletal muscle <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span> (<span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">twitching</span>), injury to nerves adjacent to injection site, and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span></p>
<p><span class="Italics">Psychiatric</span>—Emergence <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, and <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> may occur, especially in the presence of <span class="product-label-link" type="condition" conceptid="439502" conceptname="Postoperative pain">postoperative pain</span></p>
<p><span class="Italics">Gastrointestinal</span>—<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, and <span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">liver function tests abnormal</span></p>
<p><span class="Italics">Allergic</span>—<span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Erythema</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, and cases of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> have been reported rarely</p>
<p><span class="Italics">Other</span>—Other adverse reactions include <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> at injection site, <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">salivation</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, and <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span></p>
<p>For medical advice about adverse reactions contact your medical professional.  To report SUSPECTED ADVERSE REACTIONS, contact JHP at 1-866-923-2547 or MEDWATCH at 1-800-FDA-1088 (1-800-332-1088) or http://www.fda.gov/medwatch/.</p>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="section-9"></a><p></p>
<h1>DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<div class="Section" data-sectionCode="34085-1">
<a name="section-9.1"></a><p></p>
<h2>Controlled Substance</h2>
<p class="First">Brevital Sodium is a Schedule IV drug.</p>
</div>
<div class="Section" data-sectionCode="34087-7">
<a name="section-9.2"></a><p></p>
<h2></h2>
<p class="First">Brevital Sodium may be habit-forming.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-10"></a><p></p>
<h1>OVERDOSAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.1"></a><p></p>
<h2>Signs and Symptoms</h2>
<p class="First">The onset of toxicity following an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of intravenously administered methohexital will be within seconds of the infusion. If methohexital is administered rectally or is ingested, the onset of toxicity may be delayed. The manifestations of an ultrashort-acting barbiturate in <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> include central nervous system <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, loss of peripheral <span class="product-label-link" type="condition" conceptid="4089490" conceptname="Vascular resistance">vascular resistance</span>, and muscular <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span> ranging from <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">twitching</span> to convulsive-like movements. Other findings may include <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>. Following massive exposure to any barbiturate, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">circulatory collapse</span> with loss of peripheral vascular tone, and <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> may occur.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10.2"></a><p></p>
<h2>Treatment</h2>
<p class="First">To obtain up-to-date information about the treatment of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, a good resource is your certified Regional Poison Control Center. Telephone numbers of certified poison control centers are listed in the <span class="Italics">Physicians' Desk Reference (PDR</span>). In managing overdosage, consider the possibility of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">multiple drug overdoses</span>, interaction among drugs, and unusual drug kinetics in your patient.</p>
<p>Establish an airway and ensure oxygenation and ventilation. Resuscitative measures should be initiated promptly. For <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, intravenous fluids should be administered and the patient's legs raised. If desirable increase in blood pressure is not obtained, vasopressor and/or inotropic drugs may be used as dictated by the clinical situation.</p>
<p>For <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, diazepam intravenously and phenytoin may be required. If the <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> are refractory to diazepam and phenytoin, general anesthesia and <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span> with a neuromuscular blocking agent may be necessary.</p>
<p>Protect the patient's airway and support ventilation and perfusion. Meticulously monitor and maintain, within acceptable limits, the patient's vital signs, blood gases, serum electrolytes, etc. Absorption of drugs from the gastrointestinal tract may be decreased by giving activated charcoal, which, in many cases, is more effective than <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> or lavage; consider charcoal instead of or in addition to gastric emptying. Repeated doses of charcoal over time may hasten elimination of some drugs that have been absorbed. Safeguard the patient's airway when employing gastric emptying or charcoal.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-11"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Facilities for assisting ventilation and administering oxygen are necessary adjuncts for all routes of administration of anesthesia. Since cardiorespiratory arrest may occur, patients should be observed carefully during and after use of Brevital Sodium. Age- and size-appropriate resuscitative equipment (ie, intubation and cardioversion equipment, oxygen, suction, and a secure intravenous line) and personnel qualified in its use must be immediately available.</p>
<p>Preanesthetic medication is generally advisable. Brevital Sodium may be used with any of the recognized preanesthetic medications.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.1"></a><p></p>
<h2>Preparation of Solution</h2>
<p class="First">FOLLOW DILUTION INSTRUCTIONS EXACTLY.</p>
<p>Solutions of Brevital Sodium should be freshly prepared and used promptly. Reconstituted solutions of Brevital Sodium are chemically stable at room temperature for 24 hours.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2"></a><p></p>
<h2>Diluents</h2>
<p class="First">DO NOT USE DILUENTS CONTAINING BACTERIOSTATS.</p>
<p>Preferred diluent: Sterile Water for Injection </p>
<p>Acceptable diluents: 5% Dextrose Injection (for IV or rectal administration only), 0.9% Sodium Chloride Injection</p>
<p>Incompatible diluents: Lactated Ringer's Injection</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.1"></a><p></p>
<h3>Dilution Instructions</h3>
<p class="First">1% solutions (10 mg/mL) should be prepared for intravenous use. Contents of vials should be diluted as follows:</p>
<table width="90%">
<caption><span>FOR INTRAVENOUS ADMINISTRATION</span></caption>
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="35%">
<col align="center" valign="middle" width="45%">
<thead><tr class="First Last">
<th class="Lrule" align="center">Strength</th>
<th align="center">Amount of Diluent to Be Added to the Contents of the Vial</th>
<th class="Rrule" align="center">For 1% methohexital solution</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule" align="center">200 mg</td>
<td align="center">20 mL</td>
<td class="Rrule" align="center">no further dilution needed</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center">500 mg</td>
<td align="center">50 mL</td>
<td class="Rrule" align="center">no further dilution needed</td>
</tr>
<tr class="Last">
<td class="Lrule" align="center">2.5 g</td>
<td align="center">15 mL</td>
<td class="Rrule" align="center">add to 235 mL diluent for 250 mL total volume</td>
</tr>
</tbody>
</table>
<p>When the first dilution is made with the 2.5 g, the solution in the vial will be yellow. When further diluted to make a 1% solution, it must be <span class="Italics">clear and colorless</span> or should not be used. For continuous drip anesthesia, prepare a 0.2% solution by adding 500 mg of Brevital Sodium to 250 mL of diluent. For this dilution, either 5% glucose solution or isotonic (0.9%) sodium chloride solution is recommended instead of distilled water in order to avoid extreme hypotonicity.</p>
<p>For <span class="Italics">intramuscular</span> administration, contents of the vials should be diluted as follows:</p>
<table width="90%">
<caption><span>FOR INTRAMUSCULAR ADMINISTRATION</span></caption>
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="35%">
<col align="center" valign="middle" width="45%">
<thead><tr class="First Last">
<th class="Lrule" align="center">Strength</th>
<th align="center">Amount of Diluent<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a> to Be Added to the Contents of the Vial</th>
<th class="Rrule" align="center">Methohexital Concentration after Dilution</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Sterile Water for Injection or 0.9% Sodium Chloride Injection only.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule" align="center">200 mg </td>
<td align="center">4 mL</td>
<td class="Rrule" align="center">5% Solution (50 mg/mL)</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center">500 mg </td>
<td align="center">10 mL</td>
<td class="Rrule" align="center">5% Solution (50 mg/mL)</td>
</tr>
<tr class="Last">
<td class="Lrule" align="center">2.5 g vial</td>
<td align="center">50 mL</td>
<td class="Rrule" align="center">5% Solution (50 mg/mL)</td>
</tr>
</tbody>
</table>
<p>For <span class="Italics">recta</span>l administration, contents of the vials should be diluted as follows:</p>
<table width="90%">
<caption><span>FOR RECTAL ADMINISTRATION</span></caption>
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="35%">
<col align="center" valign="middle" width="45%">
<thead><tr class="First Last">
<th class="Lrule" align="center">Strength</th>
<th align="center">Amount of Diluent to Be Added to the Contents of the Vial</th>
<th class="Rrule" align="center">Methohexital Concentration after Dilution</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule" align="center">200 mg vial</td>
<td align="center">20 mL</td>
<td class="Rrule" align="center">1% Solution (10 mg/mL)</td>
</tr>
<tr class="Botrule">
<td class="Lrule" align="center">500 mg vial</td>
<td align="center">50 mL</td>
<td class="Rrule" align="center">1% Solution (10 mg/mL)</td>
</tr>
<tr class="Last" valign="top">
<td class="Lrule" align="center">2.5 g vial<br> (larger vial needed)</td>
<td align="center">250 mL</td>
<td class="Rrule" align="center">1% Solution (10 mg/mL)</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3"></a><p></p>
<h2>Administration</h2>
<p class="First">Dosage is highly individualized; the drug should be administered only by those completely familiar with its quantitative differences from other barbiturate anesthetics.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.1"></a><p></p>
<h3>Adults</h3>
<p class="First">Brevital Sodium is administered intravenously in a concentration of no higher than 1%. Higher concentrations markedly increase the incidence of muscular movements and irregularities in respiration and blood pressure.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.1.1"></a><p></p>
<h4>Induction of anesthesia</h4>
<p class="First">For induction of anesthesia, a 1% solution is administered at a rate of about 1 mL/5 seconds. Gaseous anesthetics and/or skeletal muscle relaxants may be administered concomitantly. The dose required for induction may range from 50 to 120 mg or more but averages about 70 mg. The usual dosage in adults ranges from 1 to 1.5 mg/kg. The induction dose usually provides anesthesia for 5 to 7 minutes.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.1.2"></a><p></p>
<h4>Maintenance of anesthesia</h4>
<p class="First">Maintenance of anesthesia may be accomplished by intermittent injections of the 1% solution or, more easily, by continuous intravenous drip of a 0.2% solution. Intermittent injections of about 20 to 40 mg (2 to 4 mL of a 1% solution) may be given as required, usually every 4 to 7 minutes. For continuous drip, the average rate of administration is about 3 mL of a 0.2% solution/minute (1 drop/second). The rate of flow must be individualized for each patient. For longer surgical procedures, gradual reduction in the rate of administration is recommended (see discussion of prolonged administration in <span class="Bold"><a href="#W">WARNINGS</a></span>). Other parenteral agents, usually narcotic analgesics, are ordinarily employed along with Brevital Sodium during longer procedures.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.2"></a><p></p>
<h3>Pediatric Patients</h3>
<p class="First">Brevital Sodium is administered intramuscularly in a 5% concentration and administered rectally as a 1% solution.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.2.1"></a><p></p>
<h4>Induction of anesthesia</h4>
<p class="First">For the induction of anesthesia by the intramuscular route of administration, the usual dose ranges from 6.6 to 10 mg/kg of the 5% concentration. For rectal administration, the usual dose for induction is 25 mg/kg using the 1% solution. </p>
<p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.</p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12"></a><p></p>
<h1>COMPATIBILITY INFORMATION</h1>
<p class="First">Solutions of Brevital Sodium should not be mixed in the same syringe or administered simultaneously during intravenous infusion through the same needle with acid solutions, such as atropine sulfate, metocurine iodide, and succinylcholine chloride. Alteration of pH may cause free barbituric acid to be precipitated. Solubility of the soluble sodium salts of barbiturates, including Brevital Sodium, is maintained only at a relatively high (basic) pH.</p>
<p> Because of numerous requests from anesthesiologists for information regarding the chemical compatibility of these mixtures, the following chart contains information obtained from compatibility studies in which a 1% solution of Brevital Sodium was mixed with therapeutic amounts of agents whose solutions have a low (acid) pH.</p>
<table width="100%">
<col align="left" valign="bottom" width="25%">
<col align="center" valign="bottom" width="12%">
<col align="center" valign="bottom" width="12%">
<col align="center" valign="bottom" width="12%">
<col align="center" valign="bottom" width="12%">
<col align="center" valign="bottom" width="17%">
<col align="center" valign="bottom" width="10%">
<thead><tr class="First Last">
<th align="left">Active Ingredient</th>
<th align="center">Potency per mL</th>
<th align="center">Volume Used</th>
<th align="center">Immediate</th>
<th align="center">15 min</th>
<th align="center">Physical Change<br>30 min</th>
<th align="center">1 h</th>
</tr></thead>
<tbody>
<tr class="First">
<td align="left"><span class="Bold">Brevital Sodium</span></td>
<td align="center"><span class="Bold">10 mg</span></td>
<td align="center"><span class="Bold">10 mL</span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"><span class="Bold">CONTROL</span></td>
<td align="center"></td>
</tr>
<tr>
<td align="left"><span class="Bold">Atropine Sulfate</span></td>
<td align="center"><span class="Bold">1/150 gr</span></td>
<td align="center"><span class="Bold">1 mL</span></td>
<td align="center"><span class="Bold">None</span></td>
<td align="center"><span class="Bold">Haze</span></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left"><span class="Bold">Atropine Sulfate</span></td>
<td align="center"><span class="Bold">1/100 gr</span></td>
<td align="center"><span class="Bold">1 mL</span></td>
<td align="center"><span class="Bold">None</span></td>
<td align="center"><span class="Bold">Ppt</span></td>
<td align="center"><span class="Bold">Ppt</span></td>
<td align="center"></td>
</tr>
<tr>
<td align="left"><span class="Bold">Succinylcholine chloride</span></td>
<td align="center"><span class="Bold">0.5 mg</span></td>
<td align="center"><span class="Bold">4 mL</span></td>
<td align="center"><span class="Bold">None</span></td>
<td align="center"><span class="Bold">None</span></td>
<td align="center"><span class="Bold">Haze</span></td>
<td align="center"></td>
</tr>
<tr>
<td align="left"><span class="Bold">Succinylcholine chloride</span></td>
<td align="center"><span class="Bold">1 mg</span></td>
<td align="center"><span class="Bold">4 mL</span></td>
<td align="center"><span class="Bold">None</span></td>
<td align="center"><span class="Bold">None</span></td>
<td align="center"><span class="Bold">Haze</span></td>
<td align="center"></td>
</tr>
<tr>
<td align="left"><span class="Bold">Metocurine Iodide</span></td>
<td align="center"><span class="Bold">0.5 mg</span></td>
<td align="center"><span class="Bold">4 mL</span></td>
<td align="center"><span class="Bold">None</span></td>
<td align="center"><span class="Bold">None</span></td>
<td align="center"><span class="Bold">Ppt</span></td>
<td align="center"></td>
</tr>
<tr>
<td align="left"><span class="Bold">Metocurine Iodide</span></td>
<td align="center"><span class="Bold">1 mg</span></td>
<td align="center"><span class="Bold">4 mL</span></td>
<td align="center"><span class="Bold">None</span></td>
<td align="center"><span class="Bold">None</span></td>
<td align="center"><span class="Bold">Ppt</span></td>
<td align="center"></td>
</tr>
<tr>
<td align="left"><span class="Bold">Scopolamine hydrobromide</span></td>
<td align="center"><span class="Bold">1/120 gr</span></td>
<td align="center"><span class="Bold">1 mL</span></td>
<td align="center"><span class="Bold">None</span></td>
<td align="center"><span class="Bold">None</span></td>
<td align="center"><span class="Bold">None</span></td>
<td align="center"><span class="Bold">Haze</span></td>
</tr>
<tr class="Last">
<td align="left"><span class="Bold">Tubocurarine chloride</span></td>
<td align="center"><span class="Bold">3 mg</span></td>
<td align="center"><span class="Bold">4 mL</span></td>
<td align="center"><span class="Bold">None</span></td>
<td align="center"><span class="Bold">Haze</span></td>
<td align="center"></td>
<td align="center"></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-13"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Store between 20° to 25°C (68° to 77°F). (See USP Controlled Room Temperature.) </p>
<p>Brevital® Sodium Vials<a name="footnote-reference-2" href="#footnote-2" class="Sup">1</a>:</p>
<p>200 mg (with 12 mg of anhydrous sodium carbonate) are available as follows:</p>
<dl>
<dt> </dt>
<dd>20-mL size, single-use—10's (NDC 42023-148-10)</dd>
</dl>
<p>500 mg (with 30 mg anhydrous sodium carbonate) are available as follows:</p>
<dl>
<dt> </dt>
<dd>50-mL size, multiple dose—1's (NDC 42023-105-01)</dd>
</dl>
<p>The 2.5 g vials (with 150 mg anhydrous sodium carbonate) are available as follows:</p>
<dl>
<dt> </dt>
<dd>50-mL size, multiple dose—1's (NDC 42023-106-01)</dd>
</dl>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">1</a></dt>
<dd>In crystalline form.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14"></a><p></p>
<p class="First">Rx only</p>
<p>Prescribing Information as of February 2013.</p>
<p><span class="Bold">JHP Pharmaceuticals</span><br>						Manufactured and Distributed by:<br>JHP Pharmaceuticals, LLC<br>Rochester, MI 48307</p>
<p>3003014E</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-15"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First"><span class="Bold">NDC 54569-3912-0</span></p>
<p>Relabeled by:<br><span class="Bold">A-S Medication Solutions</span><br>Libertyville, IL 60048</p>
<br><div class="Figure"><img alt="3912-0.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=468a7188-2e77-480f-8c68-6e2e9b6b47fd&amp;name=3912-0.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>BREVITAL SODIUM 		
					</strong><br><span class="contentTableReg">methohexital sodium injection, powder, lyophilized, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54569-3912(NDC:42023-105)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS, INTRAMUSCULAR, RECTAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CIV    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>methohexital sodium</strong> (methohexital) </td>
<td class="formItem">methohexital sodium</td>
<td class="formItem">500 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM CARBONATE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54569-3912-0</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA011559</td>
<td class="formItem">11/01/2007</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>A-S Medication Solutions LLC
							(830016429)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">A-S Medication Solutions LLC</td>
<td class="formItem"></td>
<td class="formItem">830016429</td>
<td class="formItem">relabel(54569-3912)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 6/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>7f29ad1b-ea80-4485-bbac-f7101aee0705</div>
<div>Set id: 468a7188-2e77-480f-8c68-6e2e9b6b47fd</div>
<div>Version: 1</div>
<div>Effective Time: 20130605</div>
</div>
</div> <div class="DistributorName">A-S Medication Solutions LLC</div></p>
</body></html>
